Discovery of (R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor was written by Li, Hui;Tatlock, John;Linton, Angelica;Gonzalez, Javier;Jewell, Tanya;Patel, Leena;Ludlum, Sarah;Drowns, Matthew;Rahavendran, Sadayappan V.;Skor, Heather;Hunter, Robert;Shi, Stephanie T.;Herlihy, Koleen J.;Parge, Hans;Hickey, Michael;Yu, Xiu;Chau, Fannie;Nonomiya, Jim;Lewis, Cristina. And the article was included in Journal of Medicinal Chemistry in 2009.Related Products of 156761-88-5 This article mentions the following:
The HCV RNA-dependent RNA polymerase has emerged as one of the key targets for novel anti-HCV therapy development. Herein, we report the optimization of the dihydropyrone series inhibitors to improve compound aqueous solubility and reduce CYP2D6 inhibition, which led to the discovery of compound 24 (PF-00868554)(I). Compound 24 is a potent and selective HCV polymerase inhibitor with a favorable pharmacokinetic profile and has recently entered a phase II clin. evaluation in patients with genotype 1 HCV. In the experiment, the researchers used many compounds, for example, 4-Bromo-2-ethylpyridine (cas: 156761-88-5Related Products of 156761-88-5).
4-Bromo-2-ethylpyridine (cas: 156761-88-5) belongs to pyridine derivatives. Pyridine has a dipole moment and a weaker resonant stabilization than benzene (resonance energy 117 kJ·mol−1 in pyridine vs. 150 kJ·mol−1 in benzene). Pyridine groups exist in countless molecules, and their applications include catalysis, drug design, molecular recognition, and natural product synthesis.Related Products of 156761-88-5